Treatment of Antipsychotic-Related Akathisia Revisited: The Role of Serotonin 2A Receptor Antagonists.
Akathisia remains a prevalent, clinically significant, and therapeutically challenging adverse event associated with antipsychotic treatment. Compelling evidence supports therapeutic efficacy and clinical utility of agents with marked serotonin 2A receptor antagonism, primarily low-dose mirtazapine, as an effective and well-tolerated antiakathisia treatment.
From the *Tirat Carmel Mental Health Center affiliated to Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa; and †Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Michael
M
Poyurovsky
Abraham
A
Weizman
D017109:Akathisia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D006801:Humans; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology*
D014150:Antipsychotic Agents; D058830:Serotonin 5-HT2 Receptor Antagonists